AGN-231868 / AbbVie, Eurobio Scientific - LARVOL DELTA

Evaluation of tear pharmacokinetics of 2 novel anti-inflammatory molecules, following topical ocular administration in rabbits and humans. (ARVO 2025) - P2 | "Two novel molecules, AGN-242428 and AGN-231868, investigated for the management of dry eye disease (DED), were studied in rabbits and humans. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

PK/PD data • Preclinical • Dry Eye Disease • Ocular Inflammation • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P2 | N=292 | Completed | Sponsor: Allergan | Active, not recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P2 | N=292 | Active, not recruiting | Sponsor: Allergan | Recruiting ➔ Active, not recruiting | N=72 ➔ 292

Enrollment change • Enrollment closed • Dry Eye Disease • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P2; N=72; Recruiting; Sponsor: Allergan; Trial primary completion date: Sep 2021 ➔ Feb 2022

Clinical • Trial primary completion date • Dry Eye Disease • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P2; N=72; Recruiting; Sponsor: Allergan; Active, not recruiting ➔ Recruiting; Phase classification: P1/2 ➔ P2

Clinical • Enrollment open • Phase classification • Dry Eye Disease • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Active, not recruiting; Sponsor: Allergan; Trial completion date: Dec 2020 ➔ Sep 2021; Trial primary completion date: Dec 2020 ➔ Sep 2021; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Dry Eye Disease • Ocular Infections • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Recruiting; Sponsor: Allergan; Trial completion date: Sep 2020 ➔ Dec 2020

Trial completion date • Dry Eye Disease • Ocular Infections • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Recruiting; Sponsor: Allergan; Active, not recruiting ➔ Recruiting; Trial completion date: Jun 2020 ➔ Sep 2020; Trial primary completion date: Jun 2020 ➔ Sep 2020

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Ophthalmology

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Active, not recruiting; Sponsor: Allergan; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Recruiting; Sponsor: Allergan; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Not yet recruiting; Sponsor: Allergan; Trial completion date: Sep 2020 ➔ Jun 2020; Trial primary completion date: Sep 2020 ➔ Jun 2020

Clinical • Trial completion date • Trial primary completion date

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease (clinicaltrials.gov) - P1/2; N=72; Not yet recruiting; Sponsor: Allergan; Initiation date: Sep 2019 ➔ Feb 2020

Clinical • Trial initiation date